Samsung Biologics clears 3 trillion won rights offering review without FSS correction
AI Summary- Samsung Biologics secured effectiveness for its 3 trillion won rights offering without an FSS correction request.
- 2.27 million new shares will be offered at a preliminary price of 1.322 million won each.
- Existing shareholders subscribe November 9–10, followed by public sales and November 30 listing.